Antagonists of mcp-1 function and methods of use thereof
CA 2442776 A1 · Owner: Anuskiewicz, Steven E. · Inventors: Inagaki, Hideaki; Robinson, Louise; Meng, Fanying
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to chemical compounds Ia IIa and IIIa, pharmaceutical compositions comprising said compounds uses of said compounds , and compositions methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically this , invention relates to novel compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases especially , those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy inflammatory bowel , disease, Crohn's …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 28, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 28, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 28, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.